Pacira Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on September 18, 2019, by Pacira Biosciences, Inc. (PCRX), a Delaware corporation. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to historical compensation arrangements with the newly appointed director's affiliated entity:
- 2018 Consulting Fees: Approximately $481,000 paid to Christie LLC.
- 2019 Consulting Fees: Approximately $320,000 paid to Christie LLC.
- Stock Options: 35,000 shares granted to Christie LLC with exercise prices of $34.38 and $42.54 per share.
Material Changes
The primary material change is the appointment of Christopher J. Christie as a Class III director on September 18, 2019. Concurrently, the consulting arrangement with Christie LLC was terminated effective as of the date of his appointment. Mr. Christie was not appointed to any board committees at the time of this filing.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. It notes that Mr. Christie will receive the Company's standard compensation for non-employee directors. The document states there are no other understandings or arrangements regarding his selection and no other reportable transactions under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the standard compensation package for non-employee directors to understand Mr. Christie's future remuneration.
- Confirm the vesting schedule and current status of the 35,000 stock options previously granted to Christie LLC.
- Review the Company's proxy statement or subsequent filings to determine if Mr. Christie has been assigned to any board committees post-appointment.
- Check for any related party transaction disclosures in the most recent 10-K or 10-Q regarding the terminated consulting agreement.